Dalbavancin for the Treatment of Complicated Gram-Positive Skin and Soft Tissue Infections.
Int J Low Extrem Wounds. 2020 Jun 05;:1534734620921677
Authors: Petrakis V, Panagopoulos P, Papanas N
New antimicrobial agents have been developed to treat infections caused by methicillin-resistant Staphylococcus aureus and other multidrug-resistant pathogens. Dalbavancin is a novel semisynthetic lipoglycopeptide antibiotic, particularly active against methicillin-resistant Staphylococcus aureus. Due to its unique pharmacological characteristics and longer half-life, it can be administered once-weekly or every 15 days and in outpatient setting. Currently, it is indicated for complicated skin and soft tissue infections, but accumulating evidence points to its off-label efficacy in osteomyelitis and endocarditis. Further experience is still needed to increase our knowledge on the role of dalbavancin in a wider range of Gram-positive infections requiring prolonged antimicrobial treatment.
PMID: 32500744 [PubMed - as supplied by publisher]